Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference
source: pixabay.com

Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference

According to a press release from Sanofi, platform and poster presentations focused on the company's investigational product candidate avalglucosidase alfa are slated to be made public at the 17th annual…

Continue Reading Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference
Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant
source: pixabay.com

Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant

  According to Batten Disease News, Invitae and Axovant Gene Therapies partnered up to offer free genetic testing in North America. This will focus on children who are thought to…

Continue Reading Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant

Sanofi is Making Strides in Lysosomal Storage Disease Research

Sanofi There are an estimated 350 million rare disease patients across the world. Many conditions still don't have treatments. However, there are scientists dedicating their lives solely to this endeavor.…

Continue Reading Sanofi is Making Strides in Lysosomal Storage Disease Research
AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
source: pixabay.com

AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina.  This company is dedicated to the research of gene therapies as potential therapeutic options…

Continue Reading AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
source: pixabay.com

The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases

According to a story from Charcot-Marie-Tooth News, the Muscular Dystrophy Association (MDA) may at first seem like a group that is solely focused on helping muscular dystrophy patients, but its…

Continue Reading The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA
source: pixabay.com

Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA

According to a story from tradeshownews.vporoom.com, the Muscular Dystrophy Association (MDA) has recently announced the official approval of its Patient-Focused Drug Development (PFDD) meeting by the US Food and Drug…

Continue Reading Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA

First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease

Actus Therapeutics, a privately held portfolio company of AskBio, has recently announced through PRWeb, the initiation of patient dosing in a clinical trial testing its investigational gene therapy ACTUS-101. About Pompe…

Continue Reading First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases
Pexels / Pixabay

Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases

According to a publication from Fabry Disease News, Amicus Therapeutics has as many as 14 investigational drugs currently in development for the treatment of rare diseases including Fabry, Pompe, and…

Continue Reading Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases

Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership

Extended Collaboration  Amicus Therapeutics has just announced that they are expanding their collaboration with the University of Pennsylvania's Perelman School of Medicine for the next five years. This collaboration is…

Continue Reading Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership